肺腺癌中可变剪接调控因子KHSRP调控的差异剪接基因分析

刘晓丽; 柴文君; 孙磊; 闫明霞; 潘洪玉; 孙跃喜

doi:10.19401/j.cnki.1007-3639.2023.07.001

您当前的位置：

首页 >

文章列表页 >

肺腺癌中可变剪接调控因子KHSRP调控的差异剪接基因分析

论著 | 更新时间：2025-12-31

- 肺腺癌中可变剪接调控因子KHSRP调控的差异剪接基因分析
- Analysis of differential splicing gene by regulation of splicing regulatory protein KHSRP in lung adenocarcinoma
- 中国癌症杂志 2023年33卷第7期页码：637-645
- 作者机构：
  
  1. 复旦大学附属肿瘤医院肿瘤研究所，复旦大学上海医学院肿瘤学系，上海 200032
  2. 同济大学附属同济医院急诊医学科，上海 200065
- 作者简介：
  
  [ "刘晓丽（ORCID: 0009-0002-7379-8992），博士，助理研究员。" ]
  孙跃喜（ORCID: 0009-0007-5764-5917），学士，主治医师。
- 基金信息：
  
  国家自然科学基金面上项目(81972173);国家自然科学基金面上项目(82273371)
- DOI：10.19401/j.cnki.1007-3639.2023.07.001
  中图分类号： R734.2
- 收稿：2023-04-15，
  
  修回：2023-06-27，
  
  纸质出版：2023-07-30
- 稿件说明：
移动端阅览
刘晓丽, 柴文君, 孙磊, 等. 肺腺癌中可变剪接调控因子KHSRP调控的差异剪接基因分析[J]. 中国癌症杂志, 2023,33(7):637-645.

Xiaoli LIU, Wenjun CHAI, Lei SUN, et al. Analysis of differential splicing gene by regulation of splicing regulatory protein KHSRP in lung adenocarcinoma[J]. China Oncology, 2023, 33(7): 637-645.
刘晓丽, 柴文君, 孙磊, 等. 肺腺癌中可变剪接调控因子KHSRP调控的差异剪接基因分析[J]. 中国癌症杂志, 2023,33(7):637-645. DOI： 10.19401/j.cnki.1007-3639.2023.07.001.

Xiaoli LIU, Wenjun CHAI, Lei SUN, et al. Analysis of differential splicing gene by regulation of splicing regulatory protein KHSRP in lung adenocarcinoma[J]. China Oncology, 2023, 33(7): 637-645. DOI： 10.19401/j.cnki.1007-3639.2023.07.001.

摘要

背景与目的：

可变剪接在细胞增殖、生长、凋亡及分化等复杂的蛋白质功能调控中发挥着至关重要的作用，能参与包括肿瘤在内的多种疾病的发生、发展过程，目前大多数可变剪接调控因子的功能及其作用机制尚不清楚。本研究旨在探讨KH型剪接调控蛋白（KH-type splicing regulatory protein，KHSRP）在肺腺癌中的差异剪接靶基因及靶基因的表达与患者预后及免疫细胞功能的相关性。

方法：

通过高通量可变剪接测序，筛选KHSRP下游差异剪接靶基因。通过肿瘤免疫评估资源（Tumor IMmune Estimation Resource，TIMER）和阿拉巴马大学伯明翰分校癌症数据分析门户（the University of Alabama at Birmingham cancer data analysis portal，ULCAN）分析KHSRP下游差异剪接靶基因在肺腺癌中的表达。通过Kaplan数据库分析KHSRP下游差异剪接靶基因的表达与患者预后的相关性。通过TIMER免疫模块分析KHSRP下游差异剪接靶基因与免疫细胞功能的相关性。

结果：

NUMB

、

ADD

3及

LIMCH

1为KHSRP的下游关键可变剪接靶基因。

NUMB

、

ADD

3及

LIMCH

1在肺腺癌肿瘤组织中均呈低表达，其低表达者预后不良。

NUMB

、

ADD

3及

LIMCH

1与免疫细胞功能呈正相关。

结论：

在肺腺癌中，

NUMB

、

ADD

3及

LIMCH

1为

KHSRP

的差异剪接靶基因，且

NUMB

、

ADD

3及

LIMCH

1低表达会导致预后不良，并且与免疫细胞功能呈正相关。

Abstract

Background and purpose:

Alternative splicing plays a crucial role in the functions and regulation of complex proteins such as cell proliferation

growth

apoptosis and differentiation

and can cause the occurrence and development of various diseases

including cancer. Currently

the functions and molecular mechanisms of most alternative splicing factors are not clear. The purpose of this study was to explore the differential splicing target genes of KH-type splicing regulatory protein (KHSRP) in lung adenocarcinoma and their correlation with prognosis and immune cell function.

Methods:

Screening downstream dif

ferential splicing target genes of KHSRP was carried out through high-throughput variable splicing sequencing. We analyzed the expressions of KHSRP downstream differential splicing target genes in lung adenocarcinoma through cancer databases Tumor IMmune Estimation Resource (TIMER) and the University of Alabama at Birmingham cancer data analysis portal (ULCAN). We also analyzed the correlation between the expression of differential splicing target genes downstream of KHSRP and prognosis through Kaplan database. The correlation between downstream differential splicing target genes of KHSRP and immune cell function was analyzed through the TIMER immune module.

Results:

NUMB endocytic adaptor protein (NUMB)

adducin 3 (ADD3) and LIM and calponin homology domains 1 (

LIMCH

1) were key downstream variable splicing target genes of KHSRP.

NUMB

ADD

3 and

LIMCH

1 were all expressed at low level in lung adenocarcinoma tumor tissue. Low expressions of

NUMB

ADD

3 and

LIMCH

1 in lung cancer leaded to poor prognosis. NUMB

ADD3 and LIMCH1 were positively correlated with immune cell function.

Conclusion:

In lung adenocarcinoma

NUMB

ADD

3 and

LIMCH

1 are differential splicing target genes of KHSRP

their low expression levels indicate poor prognosis

and they are positively correlated with immune cell function.

关键词

Keywords

references

BRAY F , FERLAY J , SOERJOMATARAM I , et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2018 , 68 ( 6 ): 394 - 424 . DOI: 10.3322/caac.v68.6 http://doi.org/10.3322/caac.v68.6 http://doi.wiley.com/10.3322/caac.v68.6 http://doi.wiley.com/10.3322/caac.v68.6

TIAN C H , WANG Y , YU H P , et al . A gene expression map of shoot domains reveals regulatory mechanisms [J ] . Nat Commun , 2019 , 10 ( 1 ): 141 . DOI: 10.1038/s41467-018-08083-z http://doi.org/10.1038/s41467-018-08083-z

LI M M , WU P D , YANG Z C , et al . miR-193a-5p promotes pancreatic cancer cell metastasis through SRSF6-mediated alternative splicing of OGDHL and ECM1 [J ] . Am J Cancer Res , 2020 , 10 ( 1 ): 38 - 59 .

JBARA A , LIN K T , STOSSEL C , et al . RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer [J ] . Nature , 2023 , 617 ( 7959 ): 147 - 153 . DOI: 10.1038/s41586-023-05820-3 http://doi.org/10.1038/s41586-023-05820-3

PELLARIN I , DALL’ACQUA A , GAMBELLI A , et al . Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity [J ] . Oncogene , 2020 , 39 ( 22 ): 4390 - 4403 . DOI: 10.1038/s41388-020-1292-6 http://doi.org/10.1038/s41388-020-1292-6

HE Y T , OUYANG Z B , LIU W W , et al . TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing [J ] . Oncogene , 2023 , 42 ( 1 ): 49 - 61 . DOI: 10.1038/s41388-022-02539-9 http://doi.org/10.1038/s41388-022-02539-9

HU X H , HARVEY S E , ZHENG R , et al . The RNA-binding protein AKAP8 suppresses tumor metastasis by antagonizing EMT-associated alternative splicing [J ] . Nat Commun , 2020 , 11 ( 1 ): 486 . DOI: 10.1038/s41467-020-14304-1 http://doi.org/10.1038/s41467-020-14304-1

YADAV P , PANDEY A , KAKANI P , et al . Hypoxia-induced loss of SRSF2-dependent DNA methylation promotes CTCF-mediated alternative splicing of VEGFA in breast cancer [J ] . iScience , 2023 , 26 ( 6 ): 106804 . DOI: 10.1016/j.isci.2023.106804 http://doi.org/10.1016/j.isci.2023.106804 https://linkinghub.elsevier.com/retrieve/pii/S2589004223008817 https://linkinghub.elsevier.com/retrieve/pii/S2589004223008817

JIA R B , CHAI P W , WANG S Z , et al . m6A modification suppresses ocular melanoma through modulating HINT2 mRNA translation [J ] . Mol Cancer , 2019 , 18 ( 1 ): 161 . DOI: 10.1186/s12943-019-1088-x http://doi.org/10.1186/s12943-019-1088-x

LOBAS A A , SOLOVYEVA E M , LEVITSKY L I , et al . Identification of alternative splicing in proteomes of human melanoma cell lines without RNA sequencing data [J ] . Int J Mol Sci , 2023 , 24 ( 3 ): 2466 . DOI: 10.3390/ijms24032466 http://doi.org/10.3390/ijms24032466 https://www.mdpi.com/1422-0067/24/3/2466 https://www.mdpi.com/1422-0067/24/3/2466

SONG X , WAN X C , HUANG T Z , et al . SRSF3-regulated RNA alternative splicing promotes glioblastoma tumorigenicity by affecting multiple cellular processes [J ] . Cancer Res , 2019 , 79 ( 20 ): 5288 - 5301 . DOI: 10.1158/0008-5472.CAN-19-1504 http://doi.org/10.1158/0008-5472.CAN-19-1504

LARIONOVA T D , BASTOLA S , AKSININA T E , et al . Alternative RNA splicing modulates ribosomal composition and determines the spatial phenotype of glioblastoma cells [J ] . Nat Cell Biol , 2022 , 24 ( 10 ): 1541 - 1557 . DOI: 10.1038/s41556-022-00994-w http://doi.org/10.1038/s41556-022-00994-w

KING P H , CHEN C Y . Role of KSRP in control of type Ⅰ interferon and cytokine expression [J ] . J Interferon Cytokine Res , 2014 , 34 ( 4 ): 267 - 274 . DOI: 10.1089/jir.2013.0143 http://doi.org/10.1089/jir.2013.0143 http://www.liebertpub.com/doi/10.1089/jir.2013.0143 http://www.liebertpub.com/doi/10.1089/jir.2013.0143

BRADLEY R K , ANCZUKÓW O . RNA splicing dysregulation and the hallmarks of cancer [J ] . Nat Rev Cancer , 2023 , 23 ( 3 ): 135 - 155 . DOI: 10.1038/s41568-022-00541-7 http://doi.org/10.1038/s41568-022-00541-7

AGRAWAL A A , YU L , SMITH P G , et al . Targeting splicing abnormalities in cancer [J ] . Curr Opin Genet Dev , 2018 , 48 : 67 - 74 . DOI: S0959-437X(17)30088-6 http://doi.org/S0959-437X(17)30088-6

CLIMENTE-GONZÁLEZ H , PORTA-PARDO E , GODZIK A , et al . The functional impact of alternative splicing in cancer [J ] . Cell Rep , 2017 , 20 ( 9 ): 2215 - 2226 . DOI: 10.1016/j.celrep.2017.08.012 http://doi.org/10.1016/j.celrep.2017.08.012 https://linkinghub.elsevier.com/retrieve/pii/S221112471731104X https://linkinghub.elsevier.com/retrieve/pii/S221112471731104X

YAN M X , SUN L , LI J , et al . RNA-binding protein KHSRP promotes tumor growth and metastasis in non-small cell lung cancer [J ] . J Exp Clin Cancer Res , 2019 , 38 ( 1 ): 478 . DOI: 10.1186/s13046-019-1479-2 http://doi.org/10.1186/s13046-019-1479-2

MIN H , TURCK C W , NIKOLIC J M , et al . A new regulatory protein, KSRP, mediates exon inclusion through an intronic splicing enhancer [J ] . Genes Dev , 1997 , 11 ( 8 ): 1023 - 1036 . DOI: 10.1101/gad.11.8.1023 http://doi.org/10.1101/gad.11.8.1023 http://genesdev.cshlp.org/lookup/doi/10.1101/gad.11.8.1023 http://genesdev.cshlp.org/lookup/doi/10.1101/gad.11.8.1023

BECHARA E G , SEBESTYÉN E , BERNARDIS I , et al . RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation [J ] . Mol Cell , 2013 , 52 ( 5 ): 720 - 733 . DOI: 10.1016/j.molcel.2013.11.010 http://doi.org/10.1016/j.molcel.2013.11.010

WANG J Z , FU X , FANG Z Y , et al . QKI-5 regulates the alternative splicing of cytoskeletal gene ADD3 in lung cancer [J ] . J Mol Cell Biol , 2021 , 13 ( 5 ): 347 - 360 . DOI: 10.1093/jmcb/mjaa063 http://doi.org/10.1093/jmcb/mjaa063 https://academic.oup.com/jmcb/article/13/5/347/5983332 https://academic.oup.com/jmcb/article/13/5/347/5983332

LECHUGA S , AMIN P H , WOLEN A R , et al . Adducins inhibit lung cancer cell migration through mechanisms involving regulation of cell-matrix adhesion and cadherin-11 expression [J ] . Biochim Biophys Acta Mol Cell Res , 2019 , 1866 ( 3 ): 395 - 408 . DOI: 10.1016/j.bbamcr.2018.10.001 http://doi.org/10.1016/j.bbamcr.2018.10.001 https://linkinghub.elsevier.com/retrieve/pii/S016748891830421X https://linkinghub.elsevier.com/retrieve/pii/S016748891830421X

WANG Y B , BAO Y F , ZHANG S R , et al . Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targets [J ] . Sci China Life Sci , 2020 , 63 ( 4 ): 469 - 484 . DOI: 10.1007/s11427-019-1605-0 http://doi.org/10.1007/s11427-019-1605-0

REN P P , LU L Y , CAI S S , et al . Alternative splicing: a new cause and potential therapeutic target in autoimmune disease [J ] . Front Immunol , 2021 , 12 : 713540 . DOI: 10.3389/fimmu.2021.713540 http://doi.org/10.3389/fimmu.2021.713540 https://www.frontiersin.org/articles/10.3389/fimmu.2021.713540/full https://www.frontiersin.org/articles/10.3389/fimmu.2021.713540/full

PAUCEK R D , BALTIMORE D , LI G D . The cellular immunotherapy revolution: arming the immune system for precision therapy [J ] . Trends Immunol , 2019 , 40 ( 4 ): 292 - 309 . DOI: S1471-4906(19)30025-0 http://doi.org/S1471-4906(19)30025-0

LIU Y T , YAN X , ZHANG F , et al . TCR-T immunotherapy: the challenges and solutions [J ] . Front Oncol , 2021 , 11 : 794183 . DOI: 10.3389/fonc.2021.794183 http://doi.org/10.3389/fonc.2021.794183 https://www.frontiersin.org/articles/10.3389/fonc.2021.794183/full https://www.frontiersin.org/articles/10.3389/fonc.2021.794183/full

SELLARS M C , WU C J , FRITSCH E F . Cancer vaccines: building a bridge over troubled waters [J ] . Cell , 2022 , 185 ( 15 ): 2770 - 2788 . DOI: 10.1016/j.cell.2022.06.035 http://doi.org/10.1016/j.cell.2022.06.035

JAYASINGHE R G , CAO S , GAO Q S , et al . Systematic analysis of splice-site-creating mutations in cancer [J ] . Cell Rep , 2018 , 23 ( 1 ): 270 - 281.e3 . DOI: S2211-1247(18)30397-8 http://doi.org/S2211-1247(18)30397-8

KAHLES A , LEHMANN K V , TOUSSAINT N C , et al . Comprehensive analysis of alternative splicing across tumors from 8, 705 patients [J ] . Cancer Cell , 2018 , 34 ( 2 ): 211 - 224 .e6. DOI: 10.1016/j.ccell.2018.07.001 http://doi.org/10.1016/j.ccell.2018.07.001 https://linkinghub.elsevier.com/retrieve/pii/S1535610818303064 https://linkinghub.elsevier.com/retrieve/pii/S1535610818303064

BURBAGE M , ROCAÑÍN-ARJÓ A , BAUDON B , et al . Epigenetically controlled tumor antigens derived from splice junctions between exons and transposable elements [J ] . Sci Immunol , 2023 , 8 ( 80 ): eabm6360 . DOI: 10.1126/sciimmunol.abm6360 http://doi.org/10.1126/sciimmunol.abm6360 https://www.science.org/doi/10.1126/sciimmunol.abm6360 https://www.science.org/doi/10.1126/sciimmunol.abm6360

FRANKIW L , BALTIMORE D , LI G D . Alternative mRNA splicing in cancer immunotherapy [J ] . Nat Rev Immunol , 2019 , 19 ( 11 ): 675 - 687 . DOI: 10.1038/s41577-019-0195-7 http://doi.org/10.1038/s41577-019-0195-7

浏览量

4996

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

LncRNA PKD2-2-3对肺腺癌细胞增殖、克隆形成、迁移及侵袭能力的影响

基于高分辨率CT征象建立logistic回归模型对IA期肺腺癌高级别模式的预测价值

构建并验证nomogram模型预测ⅠA期肺腺癌肺泡间转移

整合素β3在肺腺癌骨转移中的作用及应用价值

GOLM1调控PI3K/AKT/mTOR信号转导通路促进肺腺癌细胞增殖、侵袭和迁移的机制研究